Werewolf Therapeutics (HOWL) Competitors $1.11 +0.03 (+2.78%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$1.10 -0.01 (-0.45%) As of 05/22/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOWL vs. PRME, INMB, TLSA, MOLN, ELDN, OGI, INBX, PRQR, HURA, and DMACShould you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Prime Medicine (PRME), INmune Bio (INMB), Tiziana Life Sciences (TLSA), Molecular Partners (MOLN), Eledon Pharmaceuticals (ELDN), Organigram (OGI), Inhibrx (INBX), ProQR Therapeutics (PRQR), TuHURA Biosciences (HURA), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Werewolf Therapeutics vs. Prime Medicine INmune Bio Tiziana Life Sciences Molecular Partners Eledon Pharmaceuticals Organigram Inhibrx ProQR Therapeutics TuHURA Biosciences DiaMedica Therapeutics Prime Medicine (NYSE:PRME) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation, community ranking and earnings. Is PRME or HOWL more profitable? Prime Medicine has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Werewolf Therapeutics' return on equity of -58.83% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Werewolf Therapeutics -578.80%-58.83%-38.45% Does the MarketBeat Community prefer PRME or HOWL? Werewolf Therapeutics received 5 more outperform votes than Prime Medicine when rated by MarketBeat users. Likewise, 70.00% of users gave Werewolf Therapeutics an outperform vote while only 65.22% of users gave Prime Medicine an outperform vote. CompanyUnderperformOutperformPrime MedicineOutperform Votes3065.22% Underperform Votes1634.78% Werewolf TherapeuticsOutperform Votes3570.00% Underperform Votes1530.00% Do analysts recommend PRME or HOWL? Prime Medicine currently has a consensus price target of $11.80, suggesting a potential upside of 859.35%. Werewolf Therapeutics has a consensus price target of $8.33, suggesting a potential upside of 650.75%. Given Prime Medicine's higher probable upside, equities research analysts plainly believe Prime Medicine is more favorable than Werewolf Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, PRME or HOWL? Werewolf Therapeutics has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$3.85M41.99-$198.13M-$1.61-0.76Werewolf Therapeutics$1.14M43.58-$37.37M-$1.67-0.66 Which has more risk and volatility, PRME or HOWL? Prime Medicine has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Does the media favor PRME or HOWL? In the previous week, Prime Medicine had 20 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 22 mentions for Prime Medicine and 2 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 0.64 beat Prime Medicine's score of 0.02 indicating that Werewolf Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in PRME or HOWL? 70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 23.5% of Prime Medicine shares are held by company insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryPrime Medicine beats Werewolf Therapeutics on 11 of the 19 factors compared between the two stocks. Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOWL vs. The Competition Export to ExcelMetricWerewolf TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.81M$6.47B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.739.0626.7119.71Price / Sales43.58251.51386.08120.53Price / CashN/A65.8538.2534.62Price / Book0.366.456.774.50Net Income-$37.37M$143.98M$3.23B$248.22M7 Day PerformanceN/A0.38%0.48%-0.78%1 Month Performance29.92%2.14%9.10%11.53%1 Year Performance-78.49%-0.33%18.56%8.99% Werewolf Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOWLWerewolf Therapeutics3.2641 of 5 stars$1.11+2.8%$8.33+650.8%-77.3%$49.81M$1.14M-0.7340PRMEPrime Medicine3.6873 of 5 stars$1.34+3.1%$13.14+880.8%-83.5%$175.76M$3.85M-0.65234Trending NewsAnalyst ForecastAnalyst RevisionINMBINmune Bio1.9258 of 5 stars$7.64+9.6%$22.80+198.4%-29.9%$175.60M$14,000.00-3.5010Positive NewsGap DownTLSATiziana Life Sciences0.93 of 5 stars$1.50-4.5%N/A+69.1%$175.27MN/A0.008Gap UpMOLNMolecular Partners1.9287 of 5 stars$4.28+4.4%$12.00+180.4%+2.4%$172.81M$4.97M-1.99180Positive NewsELDNEledon Pharmaceuticals2.1332 of 5 stars$2.87-0.7%$12.50+335.5%+1.0%$171.86MN/A-1.4310News CoveragePositive NewsAnalyst UpgradeAnalyst RevisionGap UpOGIOrganigram0.4148 of 5 stars$1.28+8.5%N/A-27.1%$171.31M$166.12M-3.37860High Trading VolumeINBXInhibrx2.1855 of 5 stars$11.71+4.7%N/A-63.6%$169.51M$200,000.000.00166PRQRProQR Therapeutics3.2189 of 5 stars$1.59-1.2%$8.75+450.3%-12.9%$167.29M$18.91M-4.97180HURATuHURA BiosciencesN/A$3.82-4.3%$12.67+231.6%N/A$166.86MN/A0.00N/AAnalyst RevisionDMACDiaMedica Therapeutics1.4697 of 5 stars$3.83+4.6%$8.00+108.9%+44.6%$164.14MN/A-6.8420Gap Up Related Companies and Tools Related Companies Prime Medicine Alternatives INmune Bio Alternatives Tiziana Life Sciences Alternatives Molecular Partners Alternatives Eledon Pharmaceuticals Alternatives Organigram Alternatives Inhibrx Alternatives ProQR Therapeutics Alternatives TuHURA Biosciences Alternatives DiaMedica Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOWL) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HOWL Stock Free HOWL Stock Alerts